Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02757313 · ClinicalTrials.gov registry record · Phase 1
Neuroscience of Marijuana Impaired Driving
A Phase 1 study of Marijuana Impairment, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT02757313: Completed Phase 1 study of Marijuana Impairment, sponsored by Yale University.
NCT02757313 is a Phase 1 study of Marijuana Impairment that has completed, run by Yale University. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02757313, a Phase 1 study of Marijuana Impairment, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Marijuana is one of the most widely used substances. However, marijuana intoxication is not fully understood in relation to driving. This study will help the investigators learn more about the potential impairments related to marijuana intoxicated driving. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure intoxication and impairment. This study will also assess levels of marijuana in blood and saliva samples. This study takes place in Hartford, Connecticut.
Primary Outcome
The Gap Acceptance Task measures strategic control of the vehicle. Strategic control of the vehicle is measured by size of headway gaps that the participant chooses in pulling out into a stream of traffic.
Conditions Studied
Interventions
- DRUG Low dose THC marijuana
- DRUG High dose THC marijuana
- DRUG Placebo marijuana
Study Locations (1)
Connecticut
- Olin Neuropsychiatry Research Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-05 |
| Phase | Phase 1 |
What the finished NCT02757313 record still lists
NCT02757313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Marijuana Impairment appearing as the primary indexed condition, and to 3 interventions - of which Low dose THC marijuana is the first listed.
NCT02757313 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02757313 about?
NCT02757313 is a clinical study titled "Neuroscience of Marijuana Impaired Driving". Marijuana is one of the most widely used substances. However, marijuana intoxication is not fully understood in relation to driving. This study will help the investigators learn more about the potential impairments related to marijuana intoxicated driving. A combination of MRI and neuropsychological...
What is the current status of trial NCT02757313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-10. Estimated completion is 2021-05.
What conditions does trial NCT02757313 study?
This clinical trial studies the following conditions: Marijuana Impairment.
What interventions are being tested in trial NCT02757313?
The interventions under investigation include: Low dose THC marijuana (DRUG), High dose THC marijuana (DRUG), Placebo marijuana (DRUG).
Who is sponsoring clinical trial NCT02757313?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02757313 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02757313's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia